Renal safety under long‐course deferasirox therapy in iron overloaded transfusion‐dependent β‐thalassemia and other anemias
Sign Up to like & getrecommendations! Published in 2018 at "American Journal of Hematology"
DOI: 10.1002/ajh.25122
Abstract: To the Editor: Renal adverse events (AE) and increases in serum creatinine (SCr) have been reported in patients with transfusional hemosiderosis treated with deferasirox. Since the core registration trials, various extension and long-term observational studies… read more here.
Keywords: value; registration; retrospective period; baseline ... See more keywords